Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.


The compounds are cherry-picked from the vast virtual chemical space of over 60B molecules. The synthesis and delivery of compounds is facilitated by Reaxense.


In the library, a selection of top modulators is provided, each marked with 38 ADME-Tox and 32 parameters related to physicochemical properties and drug-likeness. Also, every compound comes with its best docking poses, affinity scores, and activity scores, providing a comprehensive overview.


Our top-notch dedicated system is used to design specialised libraries for enzymes.


 

Fig. 1. The screening workflow of Receptor.AI

This approach involves comprehensive molecular simulations of the catalytic and allosteric binding pockets and ensemble virtual screening that accounts for their conformational flexibility. In the case of designing modulators, the structural adjustments caused by reaction intermediates are considered to improve activity and selectivity.


Our library stands out due to several important features:


  • The Receptor.AI platform compiles comprehensive data on the target protein, encompassing previous experiments, literature, known ligands, structural details, and more, leading to a higher chance of selecting the most relevant compounds.

  • Advanced molecular simulations on the platform help pinpoint potential binding sites, making the compounds in our focused library ideal for finding allosteric inhibitors and targeting cryptic pockets.

  • Receptor.AI boasts over 50 tailor-made AI models, rigorously tested and proven in various drug discovery projects and research initiatives. They are crafted for efficacy, dependability, and precision, all of which are key in creating our focused libraries.

  • Beyond creating focused libraries, Receptor.AI offers comprehensive services and complete solutions throughout the preclinical drug discovery phase. Our success-based pricing model minimises risk and maximises the mutual benefits of the project's success.


PARTNER
Receptor.AI
 
UPACC
Q86UK0

UPID:
ABCAC_HUMAN

ALTERNATIVE NAMES:
ATP-binding cassette sub-family A member 12; ATP-binding cassette transporter 12

ALTERNATIVE UPACC:
Q86UK0; Q53QE2; Q53S55; Q8IZW6; Q96JT3; Q9Y4M5

BACKGROUND:
ABCA12, known for its roles in lipid transport and skin barrier integrity, is vital for epidermal health. By facilitating the movement of glucosylceramides and influencing keratinocyte differentiation, ABCA12 underpins the formation of the protective lipid layer in the skin. Its involvement extends to cholesterol regulation and insulin secretion, highlighting its broad biological significance.

THERAPEUTIC SIGNIFICANCE:
Given ABCA12's pivotal role in conditions like autosomal recessive congenital ichthyosis, targeting this protein could revolutionize treatment paradigms. Understanding the role of ABCA12 could open doors to potential therapeutic strategies, providing a beacon of hope for patients suffering from skin barrier disorders.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.